{"protocolSection":{"identificationModule":{"nctId":"NCT05071313","orgStudyIdInfo":{"id":"CR109064"},"secondaryIdInfos":[{"id":"VAC18193RSV3005","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."}],"organization":{"fullName":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"briefTitle":"A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-10-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-04-20","type":"ACTUAL"},"completionDateStruct":{"date":"2022-10-11","type":"ACTUAL"},"studyFirstSubmitDate":"2021-09-28","studyFirstSubmitQcDate":"2021-09-28","studyFirstPostDateStruct":{"date":"2021-10-08","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-08-14","resultsFirstSubmitQcDate":"2023-08-14","resultsFirstPostDateStruct":{"date":"2023-09-13","type":"ACTUAL"},"dispFirstSubmitDate":"2023-04-17","dispFirstPostDateStruct":{"date":"2023-04-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-22","lastUpdatePostDateStruct":{"date":"2025-05-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the immunogenicity and safety of Ad26.RSV.preF-based vaccine and quadrivalent high-dose seasonal influenza vaccine when administered either concomitantly or separately."},"conditionsModule":{"conditions":["Influenza, Human Prevention","Respiratory Syncytial Viruses Prevention"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":777,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1: Coadministration (CoAd) Group","type":"EXPERIMENTAL","description":"Participants will receive Ad26.RSV.preF-based vaccine and quadrivalent high dose influenza vaccine concomitantly on Day 1 and placebo on Day 29.","interventionNames":["Biological: Ad26.RSV.preF-based vaccine","Biological: Quadrivalent High-dose Influenza Vaccine","Biological: Placebo"]},{"label":"Group 2: Control Group","type":"EXPERIMENTAL","description":"Participants will receive placebo and quadrivalent high-dose influenza vaccine on Day 1 and Ad26.RSV.preF-based vaccine on Day 29.","interventionNames":["Biological: Ad26.RSV.preF-based vaccine","Biological: Quadrivalent High-dose Influenza Vaccine","Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.RSV.preF-based vaccine","description":"Ad26.RSV.preF-based vaccine will be administered as single IM injection.","armGroupLabels":["Group 1: Coadministration (CoAd) Group","Group 2: Control Group"]},{"type":"BIOLOGICAL","name":"Quadrivalent High-dose Influenza Vaccine","description":"Quadrivalent High-dose Influenza Vaccine will be administered as IM injection.","armGroupLabels":["Group 1: Coadministration (CoAd) Group","Group 2: Control Group"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Placebo will be administered as IM injection to Ad26.RSV.preF-based vaccine.","armGroupLabels":["Group 1: Coadministration (CoAd) Group","Group 2: Control Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibodies Against Each of the Four Influenza Vaccine Strains as Measured by HI Assay","description":"Hemagglutination is a phenomenon by which the hemagglutinin protein of influenza viruses can bind to sialic acid receptors on the red blood cell membrane, thereby forming clumps and is the basis for the HI assay. GMTs of HI antibodies against each of the four influenza vaccine strains as measured by HI assay at 28 days after the administration of a quadrivalent high-dose seasonal influenza vaccine (fluzone) were reported. The analysis was performed on 2 influenza A strains \\[A/Victoria and A/Tasmania\\] and 2 influenza B strains \\[B/Washington and B/Phuket\\]).","timeFrame":"28 days after vaccination with Fluzone on Day 1 (Day 29)"},{"measure":"GMTs of Prefusion F-protein (preF) Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) on Day 29","description":"GMTs of preF antibodies at 28 days after the administration of Ad26.RSV.preF-based vaccine as assessed by ELISA on Day 29 were reported. This outcome measure was planned to be analyzed for specified arm only.","timeFrame":"28 days after vaccination with Ad26.RSV.preF-based vaccine on Day 1 (Day 29)"},{"measure":"GMTs of PreF Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) on Day 57","description":"GMTs of preF antibodies at 28 days after the administration of Ad26.RSV.preF-based vaccine as assessed by ELISA on Day 57 were reported. This outcome measure was planned to be analyzed for specified arm only.","timeFrame":"28 days after vaccination with Ad26.RSV.preF-based vaccine on Day 29 (Day 57)"}],"secondaryOutcomes":[{"measure":"Number of Participants With Solicited Local Adverse Events (AEs) After Study Vaccination 1","description":"Number of participants with solicited local AEs after study vaccination 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site). Solicited local AEs were reported separately for all vaccines because fluzone and RSV vaccine mixture (containing both Ad26. RSV. preF 1\\*10\\^11 vp and RSV preF protein 150 mcg) in group 1 were administered in opposite arms on Day 1. Similarly, fluzone and placebo in group 2 were administered in opposite arms on Day 1. Hence, the data for this outcome measure was analyzed separately for each vaccine.","timeFrame":"Up to 7 days after study vaccination 1 on Day 1 (Day 8)"},{"measure":"Number of Participants With Solicited Local AEs After Study Vaccination 2","description":"Number of participants with solicited local AEs after study vaccination 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site).","timeFrame":"Up to 7 days after study vaccination 2 on Day 29 (Day 36)"},{"measure":"Number of Participants With Solicited Systemic AEs After Study Vaccination 1","description":"Number of participants with solicited systemic AEs after study vaccination 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited systemic events included events such as fatigue, headache, nausea, and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).","timeFrame":"Up to 7 days after study vaccination 1 on Day 1 (Day 8)"},{"measure":"Number of Participants With Solicited Systemic AEs After Study Vaccination 2","description":"Number of participants with solicited systemic AEs after study vaccination 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Systemic events included events such as fatigue, headache, nausea, and myalgia, for which participants will be specifically questioned and which will be noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).","timeFrame":"Up to 7 days after study vaccination 2 on Day 29 (Day 36)"},{"measure":"Number of Participants With Unsolicited AEs After Study Vaccination 1","description":"Number of participants with unsolicited AEs after study vaccination 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were all AEs for which the participant was not specifically questioned in the participant diary.","timeFrame":"Up to 28 days after study vaccination 1 on Day 1 (Day 29)"},{"measure":"Number of Participants With Unsolicited AEs After Study Vaccination 2","description":"Number of participants with unsolicited AEs after study vaccination 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were all AEs for which the participant was not specifically questioned in the participant diary.","timeFrame":"Up to 28 days after study vaccination 2 on Day 29 (Day 57)"},{"measure":"Number of Participants With Serious Adverse Events (SAEs) Up to Study Vaccination 1","description":"Number of participants with SAEs up to study vaccination 1 were reported. SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.","timeFrame":"From Day 1 up to Day 29"},{"measure":"Number of Participants With Serious Adverse Events (SAEs) Up to Study Vaccination 2","description":"Number of participants with SAEs up to study vaccination 2 were reported. SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.","timeFrame":"From Day 29 up to 6 months after study vaccination 2 (up to 7 months)"},{"measure":"Number of Participants With Adverse Events of Special Interest (AESI) Up to Study Vaccination 1","description":"Number of participants with AESI up to study vaccination 1 were reported. Thrombosis with thrombocytopenia syndrome (TTS) was considered to be an AESI.","timeFrame":"From Day 1 up to Day 29"},{"measure":"Number of Participants With Adverse Events of Special Interest (AESI) Up to Study Vaccination 2","description":"Number of participants with AESI up to study vaccination 2 were reported. Thrombosis with thrombocytopenia syndrome (TTS) was considered to be an AESI.","timeFrame":"From Day 29 up to 6 months after study vaccination 2 (up to 7 months)"},{"measure":"Number of Seroconverted Participants After 28 Days of Administration of Influenza Vaccine","description":"Number of seroconverted participants after 28 days of administration of influenza vaccine (fluzone) were reported. Seroconversion is defined for each of the 4 influenza vaccine strains at 28 days after the administration of a quadrivalent high-dose seasonal influenza vaccine: HI titer greater than or equal to (\\>=) 1:40 in participants with a pre-vaccination HI titer of less than (\\<) 1:10, or a \\>=4-fold HI titer increase in participants with a pre-vaccination HI titer of \\>=1:10.","timeFrame":"28 days after vaccination with fluzone on Day 1 (up to Day 29)"},{"measure":"Number of Seroprotected Participants After 28 Days of Administration of Influenza Vaccine","description":"Number of seroprotected participants after 28 days of administration of influenza vaccine (fluzone) were reported. Seroprotection is defined for each of the 4 influenza vaccine strains as HI titer \\>=1:40 at 28 days after the administration of a quadrivalent high-dose seasonal influenza vaccine.","timeFrame":"28 days after vaccination with fluzone on Day 1 (up to Day 29)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Willing and able to adhere to the prohibitions and restrictions specified in this protocol\n* In the investigator's clinical judgment, the participant must be in stable health at the time of vaccination. Participants will be included on the basis of medical history and vital signs performed between informed consent from (ICF) signature and vaccination\n* Before randomization, a participant must be not intending to conceive by any methods, postmenopausal or surgically sterile\n* From the time of vaccination through 3 months after vaccination, agrees not to donate blood\n* Must be willing to provide verifiable identification, have means to be contacted and to contact the investigator during the study\n* Participant must be able to work with smartphones/tablets/computers\n\nExclusion Criteria:\n\n* History of malignancy within 5 years before screening not in the following categories: a) participants with squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix may be enrolled at the discretion of the investigator; b) participants with a history of malignancy within 5 years before screening, with minimal risk of recurrence per investigator's judgement, can be enrolled\n* Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine)\n* History of severe allergic reactions (example, anaphylaxis) to any component of the Quadrivalent high-dose influenza vaccine, including egg protein, or following a previous dose of any influenza vaccine\n* Has abnormal function of the immune system resulting from either clinical condition, chronic or recurrent use of systemic corticosteroids within 2 months prior to study vaccination, or immunomodulating agents within 6 months prior to study vaccination\n* Per medical history, participant has chronic active hepatitis B or hepatitis C infection\n* History of acute polyneuropathy (example, Guillain-Barre syndrome) or chronic idiopathic demyelinating polyneuropathy\n* Has a serious chronic disorder, example, chronic obstructive pulmonary disease or congestive heart failure, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition, including conditions placing the participant at high risk for severe influenza, for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments\n* Received vaccination with seasonal influenza vaccine for the current influenza season in the Northern Hemisphere","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Vaccines & Prevention B.V. Clinical Trial","affiliation":"Janssen Vaccines & Prevention B.V.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Ark Clinical Research","city":"Long Beach","state":"California","zip":"90806","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Research Centers of America, LLC","city":"Hollywood","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"Progressive Medical Research","city":"Port Orange","state":"Florida","zip":"32127","country":"United States","geoPoint":{"lat":29.13832,"lon":-80.99561}},{"facility":"Synexus Clinical Research US Inc","city":"The Villages","state":"Florida","zip":"32162","country":"United States","geoPoint":{"lat":28.93408,"lon":-81.95994}},{"facility":"Synexus Clinical Research US Inc","city":"Chicago","state":"Illinois","zip":"60602","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Meridian Clinical Research, LLC","city":"Rockville","state":"Maryland","zip":"20854","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Sundance Clinical Research","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Synexus Clinical Research US Inc","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Meridian Clinical Research, LLC","city":"Grand Island","state":"Nebraska","zip":"68803","country":"United States","geoPoint":{"lat":40.92501,"lon":-98.34201}},{"facility":"Meridian Clinical Research, LLC","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"Meridian Clinical Research, LLC","city":"Norfolk","state":"Nebraska","zip":"68701","country":"United States","geoPoint":{"lat":42.02834,"lon":-97.417}},{"facility":"Meridian Clinical Research, LLC","city":"Omaha","state":"Nebraska","zip":"68134","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Tekton Research Inc.","city":"Yukon","state":"Oklahoma","zip":"73099","country":"United States","geoPoint":{"lat":35.50672,"lon":-97.76254}},{"facility":"Coastal Carolina Research Center","city":"North Charleston","state":"South Carolina","zip":"29405","country":"United States","geoPoint":{"lat":32.85462,"lon":-79.97481}},{"facility":"VitaLink Research Spartanburg","city":"Spartanburg","state":"South Carolina","zip":"29303","country":"United States","geoPoint":{"lat":34.94957,"lon":-81.93205}},{"facility":"AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company","city":"Knoxville","state":"Tennessee","zip":"37920","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Optimal Research","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Tekton Research Inc.","city":"Austin","state":"Texas","zip":"78745","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"DM Clinical Research","city":"Tomball","state":"Texas","zip":"77375","country":"United States","geoPoint":{"lat":30.09716,"lon":-95.61605}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu","url":"https://www.janssen.com/clinical-trials/transparency"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV + Placebo (CoAd Group)","description":"Participants received intramuscular (IM) injection containing both adenovirus serotype 26 pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and respiratory syncytial virus prefusion F-protein (RSV preF protein) 150 micrograms (mcg) coadministered with Fluzone high-dose (HD) quadrivalent (QIV) 240 mcg IM injection on Day 1 (vaccination 1) followed by placebo IM injection on Day 29 (vaccination 2)."},{"id":"FG001","title":"Group 2: Placebo With Fluzone HD QIV + Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received placebo IM injection coadministered with Fluzone HD QIV 240 mcg IM injection on Day 1 (vaccination 1) followed by an IM injection containing both Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 29 (vaccination 2)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"389"},{"groupId":"FG001","numSubjects":"388"}]},{"type":"Received Ad26/Protein preF RSV Vaccine With Fluzone in CoAd Group at Day 1","achievements":[{"groupId":"FG000","numSubjects":"385"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Received Placebo With Fluzone in Control Group at Day 1","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"386"}]},{"type":"Received Placebo in CoAd Group at Day 29","achievements":[{"groupId":"FG000","numSubjects":"357"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Received Ad26/Protein preF RSV Vaccine in Control Group at Day 29","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"363"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"355"},{"groupId":"FG001","numSubjects":"355"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"33"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Randomized but not vaccinated","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The full analysis set (FAS) included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo).","groups":[{"id":"BG000","title":"Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV + Placebo (CoAd Group)","description":"Participants received intramuscular (IM) injection containing both adenovirus serotype 26 pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and respiratory syncytial virus prefusion F-protein (RSV preF protein) 150 micrograms (mcg) coadministered with Fluzone high-dose (HD) quadrivalent (QIV) 240 mcg IM injection on Day 1 (vaccination 1) followed by placebo IM injection on Day 29 (vaccination 2)."},{"id":"BG001","title":"Group 2: Placebo With Fluzone HD QIV + Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received placebo IM injection coadministered with Fluzone HD QIV 240 mcg IM injection on Day 1 (vaccination 1) followed by an IM injection containing both Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 29 (vaccination 2)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"385"},{"groupId":"BG001","value":"386"},{"groupId":"BG002","value":"771"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70.4","spread":"4.94"},{"groupId":"BG001","value":"70.7","spread":"4.72"},{"groupId":"BG002","value":"70.5","spread":"4.83"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"223"},{"groupId":"BG001","value":"208"},{"groupId":"BG002","value":"431"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"162"},{"groupId":"BG001","value":"178"},{"groupId":"BG002","value":"340"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"72"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"339"},{"groupId":"BG001","value":"344"},{"groupId":"BG002","value":"683"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"16"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"77"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"336"},{"groupId":"BG001","value":"333"},{"groupId":"BG002","value":"669"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"9"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"UNITED STATES","categories":[{"measurements":[{"groupId":"BG000","value":"385"},{"groupId":"BG001","value":"386"},{"groupId":"BG002","value":"771"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibodies Against Each of the Four Influenza Vaccine Strains as Measured by HI Assay","description":"Hemagglutination is a phenomenon by which the hemagglutinin protein of influenza viruses can bind to sialic acid receptors on the red blood cell membrane, thereby forming clumps and is the basis for the HI assay. GMTs of HI antibodies against each of the four influenza vaccine strains as measured by HI assay at 28 days after the administration of a quadrivalent high-dose seasonal influenza vaccine (fluzone) were reported. The analysis was performed on 2 influenza A strains \\[A/Victoria and A/Tasmania\\] and 2 influenza B strains \\[B/Washington and B/Phuket\\]).","populationDescription":"Per-protocol influenza immunogenicity (PPII) set included all randomized participants who received the first study vaccination, and for whom immunogenicity data are available for at least one of the influenza strains in the vaccine. Samples taken after participant experienced major protocol deviation expected to impact the immunogenicity outcomes were excluded from this analysis, including those who were collected out of window.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"28 days after vaccination with Fluzone on Day 1 (Day 29)","groups":[{"id":"OG000","title":"Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV + Placebo (CoAd Group)","description":"Participants received intramuscular (IM) injection containing both adenovirus serotype 26 pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and respiratory syncytial virus prefusion F-protein (RSV preF protein) 150 micrograms (mcg) coadministered with Fluzone high-dose (HD) quadrivalent (QIV) 240 mcg IM injection on Day 1 (vaccination 1) followed by placebo IM injection on Day 29 (vaccination 2)."},{"id":"OG001","title":"Group 2: Placebo With Fluzone HD QIV + Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received placebo IM injection coadministered with Fluzone HD QIV 240 mcg IM injection on Day 1 (vaccination 1) followed by an IM injection containing both Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 29 (vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"338"},{"groupId":"OG001","value":"338"}]}],"classes":[{"title":"A/Victoria","categories":[{"measurements":[{"groupId":"OG000","value":"178","lowerLimit":"145","upperLimit":"217"},{"groupId":"OG001","value":"179","lowerLimit":"146","upperLimit":"219"}]}]},{"title":"A/Tasmania","categories":[{"measurements":[{"groupId":"OG000","value":"111","lowerLimit":"89","upperLimit":"139"},{"groupId":"OG001","value":"123","lowerLimit":"98","upperLimit":"155"}]}]},{"title":"B/Washington","categories":[{"measurements":[{"groupId":"OG000","value":"93","lowerLimit":"74","upperLimit":"117"},{"groupId":"OG001","value":"84","lowerLimit":"67","upperLimit":"106"}]}]},{"title":"B/Phuket","categories":[{"measurements":[{"groupId":"OG000","value":"38","lowerLimit":"31","upperLimit":"47"},{"groupId":"OG001","value":"37","lowerLimit":"30","upperLimit":"46"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"A/Victoria","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority of Group 2 versus Group 1 in terms of the HI antibody titers against all four influenza vaccine strains 28 days after vaccination with fluzone, using a non-inferiority margin of 1.5 for the GMT ratio (Group 2/Group 1).","paramType":"Geometric Mean Ratio","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.89","ciUpperLimit":"1.14"},{"groupIds":["OG000","OG001"],"groupDescription":"A/Tasmania","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority of Group 2 versus Group 1 in terms of the HI antibody titers against all four influenza vaccine strains 28 days after vaccination with fluzone, using a non-inferiority margin of 1.5 for the GMT ratio (Group 2/Group 1).","paramType":"Geometric Mean Ratio","paramValue":"1.11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.97","ciUpperLimit":"1.28"},{"groupIds":["OG000","OG001"],"groupDescription":"B/Washington","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority of Group 2 versus Group 1 in terms of the HI antibody titers against all four influenza vaccine strains 28 days after vaccination with fluzone, using a non-inferiority margin of 1.5 for the GMT ratio (Group 2/Group 1).","paramType":"Geometric Mean Ratio","paramValue":"0.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.79","ciUpperLimit":"1.05"},{"groupIds":["OG000","OG001"],"groupDescription":"B/Phuket","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority of Group 2 versus Group 1 in terms of the HI antibody titers against all four influenza vaccine strains 28 days after vaccination with fluzone, using a non-inferiority margin of 1.5 for the GMT ratio (Group 2/Group 1).","paramType":"Geometric Mean Ratio","paramValue":"0.97","ciPctValue":"95","ciLowerLimit":"0.85","ciUpperLimit":"1.10"}]},{"type":"PRIMARY","title":"GMTs of Prefusion F-protein (preF) Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) on Day 29","description":"GMTs of preF antibodies at 28 days after the administration of Ad26.RSV.preF-based vaccine as assessed by ELISA on Day 29 were reported. This outcome measure was planned to be analyzed for specified arm only.","populationDescription":"Per-protocol RSV immunogenicity (PPRI) set included all randomized participants who received Ad26/protein preF RSV vaccine in combination with seasonal influenza vaccine in the CoAd group and Ad26/protein preF RSV vaccine alone in the control group and for which RSV immunogenicity data were available. Samples taken after participant experienced major protocol deviation expected to impact immunogenicity outcomes were excluded from this analysis, including those who were collected out of window.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ELISA units per liter (EU/L)","timeFrame":"28 days after vaccination with Ad26.RSV.preF-based vaccine on Day 1 (Day 29)","groups":[{"id":"OG000","title":"Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV + Placebo (CoAd Group)","description":"Participants received intramuscular (IM) injection containing both adenovirus serotype 26 pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and respiratory syncytial virus prefusion F-protein (RSV preF protein) 150 micrograms (mcg) coadministered with Fluzone high-dose (HD) quadrivalent (QIV) 240 mcg IM injection on Day 1 (vaccination 1) followed by placebo IM injection on Day 29 (vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"338"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2665","lowerLimit":"2209","upperLimit":"3216"}]}]}]},{"type":"PRIMARY","title":"GMTs of PreF Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) on Day 57","description":"GMTs of preF antibodies at 28 days after the administration of Ad26.RSV.preF-based vaccine as assessed by ELISA on Day 57 were reported. This outcome measure was planned to be analyzed for specified arm only.","populationDescription":"The PPRI set included all randomized participants who received Ad26/protein preF RSV vaccine in combination with seasonal influenza vaccine for the CoAd group and Ad26/protein preF RSV vaccine alone for the control group and for whom RSV immunogenicity data were available. Samples taken after participant experienced major protocol deviation expected to impact the immunogenicity outcomes were excluded from this analysis, including those who were collected out of window.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/L","timeFrame":"28 days after vaccination with Ad26.RSV.preF-based vaccine on Day 29 (Day 57)","groups":[{"id":"OG000","title":"Group 2: Placebo With Fluzone HD QIV + Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received placebo IM injection coadministered with Fluzone HD QIV 240 mcg IM injection on Day 1 (vaccination 1) followed by an IM injection containing both Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 29 (vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"318"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3206","lowerLimit":"2648","upperLimit":"3881"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Local Adverse Events (AEs) After Study Vaccination 1","description":"Number of participants with solicited local AEs after study vaccination 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site). Solicited local AEs were reported separately for all vaccines because fluzone and RSV vaccine mixture (containing both Ad26. RSV. preF 1\\*10\\^11 vp and RSV preF protein 150 mcg) in group 1 were administered in opposite arms on Day 1. Similarly, fluzone and placebo in group 2 were administered in opposite arms on Day 1. Hence, the data for this outcome measure was analyzed separately for each vaccine.","populationDescription":"The full analysis set (FAS) included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo). Here, 'N' (number of participants analyzed) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days after study vaccination 1 on Day 1 (Day 8)","groups":[{"id":"OG000","title":"Group 1: Fluzone HD QIV (CoAd Group)","description":"Participants received Fluzone HD QIV 240 mcg IM injection on Day 1 on right arm."},{"id":"OG001","title":"Group 1: Ad26/Protein preF RSV Vaccine (CoAd Group)","description":"Participants received IM injection containing both Ad26. RSV. preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1 on left arm."},{"id":"OG002","title":"Group 2: Fluzone HD QIV (Control Group)","description":"Participants received Fluzone HD QIV 240 mcg IM injection on Day 1 on right arm."},{"id":"OG003","title":"Group 2: Placebo (Control Group)","description":"Participants received placebo as an IM injection on Day 1 on left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"371"},{"groupId":"OG001","value":"371"},{"groupId":"OG002","value":"373"},{"groupId":"OG003","value":"373"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"263"},{"groupId":"OG002","value":"219"},{"groupId":"OG003","value":"98"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Local AEs After Study Vaccination 2","description":"Number of participants with solicited local AEs after study vaccination 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site).","populationDescription":"The FAS included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo). Here, 'N' (number of participants analyzed) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days after study vaccination 2 on Day 29 (Day 36)","groups":[{"id":"OG000","title":"Group 1: Placebo (CoAdGroup)","description":"Participants received placebo as an IM injection on Day 29."},{"id":"OG001","title":"Group 2: Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received IM injection containing both Ad26. RSV. preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"},{"groupId":"OG001","value":"343"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"241"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Systemic AEs After Study Vaccination 1","description":"Number of participants with solicited systemic AEs after study vaccination 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited systemic events included events such as fatigue, headache, nausea, and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).","populationDescription":"The FAS included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo). Here, 'N' (number of participants analyzed) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days after study vaccination 1 on Day 1 (Day 8)","groups":[{"id":"OG000","title":"Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV (CoAd Group)","description":"Group 1: Ad26/protein preF RSV vaccine with Fluzone HD QIV (CoAd Group) Participants received intramuscular (IM) injection containing both Ad26. RSV. preF; 1\\*10\\^11 viral particles (vp) and RSV preF protein; 150 micrograms (mcg) coadministered with Fluzone high-dose (HD) quadrivalent (QIV) 240 mcg IM injection on Day 1."},{"id":"OG001","title":"Group 2: Fluzone HD QIV With Placebo (Control Group)","description":"Participants received Fluzone HD QIV 240 mcg IM injection coadministered with placebo IM injection on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"371"},{"groupId":"OG001","value":"373"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"285"},{"groupId":"OG001","value":"181"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Systemic AEs After Study Vaccination 2","description":"Number of participants with solicited systemic AEs after study vaccination 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Systemic events included events such as fatigue, headache, nausea, and myalgia, for which participants will be specifically questioned and which will be noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).","populationDescription":"The FAS included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo). Here, 'N' (number of participants analyzed) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days after study vaccination 2 on Day 29 (Day 36)","groups":[{"id":"OG000","title":"Group 1: Placebo (CoAdGroup)","description":"Participants received placebo as an IM injection on Day 29."},{"id":"OG001","title":"Group 2: Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received IM injection containing both Ad26. RSV. preF 1\\*10\\^11 viral particles and RSV preF protein; 150 mcg on Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"},{"groupId":"OG001","value":"343"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"218"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Unsolicited AEs After Study Vaccination 1","description":"Number of participants with unsolicited AEs after study vaccination 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were all AEs for which the participant was not specifically questioned in the participant diary.","populationDescription":"The FAS included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28 days after study vaccination 1 on Day 1 (Day 29)","groups":[{"id":"OG000","title":"Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV (CoAd Group)","description":"Participants received IM injection containing both Ad26. RSV. preF; 1\\*10\\^11 viral particles and RSV preF protein; 150 mcg coadministered with Fluzone HD QIV 240 mcg IM injection on Day 1."},{"id":"OG001","title":"Group 2: Fluzone HD QIV With Placebo (Control Group)","description":"Participants received Fluzone high-dose (HD) quadrivalent (QIV) 240 micrograms (mcg) intramuscular (IM) injection coadministered with placebo IM injection on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"386"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"61"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Unsolicited AEs After Study Vaccination 2","description":"Number of participants with unsolicited AEs after study vaccination 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were all AEs for which the participant was not specifically questioned in the participant diary.","populationDescription":"The FAS included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28 days after study vaccination 2 on Day 29 (Day 57)","groups":[{"id":"OG000","title":"Group 1: Placebo (CoAdGroup)","description":"Participants received placebo as an IM injection on Day 29."},{"id":"OG001","title":"Group 2: Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received IM injection containing both Ad26. RSV. preF 1\\*10\\^11 viral particles and RSV preF protein; 150 mcg on Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"363"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"35"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs) Up to Study Vaccination 1","description":"Number of participants with SAEs up to study vaccination 1 were reported. SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.","populationDescription":"The FAS included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to Day 29","groups":[{"id":"OG000","title":"Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV (CoAd Group)","description":"Participants received IM injection containing both Ad26. RSV. preF; 1\\*10\\^11 viral particles and RSV preF protein; 150 mcg coadministered with Fluzone HD QIV 240 mcg IM injection on Day 1."},{"id":"OG001","title":"Group 2: Fluzone HD QIV With Placebo (Control Group)","description":"Participants received Fluzone high-dose (HD) quadrivalent (QIV) 240 micrograms (mcg) intramuscular (IM) injection coadministered with placebo IM injection on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"386"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs) Up to Study Vaccination 2","description":"Number of participants with SAEs up to study vaccination 2 were reported. SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.","populationDescription":"The FAS included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 29 up to 6 months after study vaccination 2 (up to 7 months)","groups":[{"id":"OG000","title":"Group 1: Placebo (CoAd Group)","description":"Participants received placebo IM injection on Day 29."},{"id":"OG001","title":"Group 2: Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received IM injection containing both Ad26. RSV. preF 1\\*10\\^11 viral particles and RSV preF protein; 150 mcg on Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"363"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events of Special Interest (AESI) Up to Study Vaccination 1","description":"Number of participants with AESI up to study vaccination 1 were reported. Thrombosis with thrombocytopenia syndrome (TTS) was considered to be an AESI.","populationDescription":"The FAS included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to Day 29","groups":[{"id":"OG000","title":"Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV (CoAd Group)","description":"Participants received IM injection containing both Ad26. RSV. preF; 1\\*10\\^11 viral particles and RSV preF protein; 150 mcg coadministered with Fluzone HD QIV 240 mcg IM injection on Day 1."},{"id":"OG001","title":"Group 2: Fluzone HD QIV With Placebo (Control Group)","description":"Participants received Fluzone HD QIV 240 mcg intramuscular (IM) injection coadministered with placebo IM injection on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"386"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events of Special Interest (AESI) Up to Study Vaccination 2","description":"Number of participants with AESI up to study vaccination 2 were reported. Thrombosis with thrombocytopenia syndrome (TTS) was considered to be an AESI.","populationDescription":"The FAS included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 29 up to 6 months after study vaccination 2 (up to 7 months)","groups":[{"id":"OG000","title":"Group 1: Placebo (CoAd Group)","description":"Participants received placebo IM injection on Day 29."},{"id":"OG001","title":"Group 2: Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received IM injection containing both Ad26. RSV. preF 1\\*10\\^11 viral particles and RSV preF protein; 150 mcg on Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"363"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverted Participants After 28 Days of Administration of Influenza Vaccine","description":"Number of seroconverted participants after 28 days of administration of influenza vaccine (fluzone) were reported. Seroconversion is defined for each of the 4 influenza vaccine strains at 28 days after the administration of a quadrivalent high-dose seasonal influenza vaccine: HI titer greater than or equal to (\\>=) 1:40 in participants with a pre-vaccination HI titer of less than (\\<) 1:10, or a \\>=4-fold HI titer increase in participants with a pre-vaccination HI titer of \\>=1:10.","populationDescription":"PPII set included all randomized participants who received the first study vaccination, and for whom immunogenicity data were available for at least one of the influenza strains in the vaccine. Samples taken after participant experienced major protocol deviation expected to impact the immunogenicity outcomes were excluded from this analysis, including those who were collected out of window.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"28 days after vaccination with fluzone on Day 1 (up to Day 29)","groups":[{"id":"OG000","title":"Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV + Placebo (CoAd Group)","description":"Participants received intramuscular (IM) injection containing both adenovirus serotype 26 pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and respiratory syncytial virus prefusion F-protein (RSV preF protein) 150 micrograms (mcg) coadministered with Fluzone high-dose (HD) quadrivalent (QIV) 240 mcg IM injection on Day 1 (vaccination 1) followed by placebo IM injection on Day 29 (vaccination 2)."},{"id":"OG001","title":"Group 2: Placebo With Fluzone HD QIV + Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received placebo IM injection coadministered with Fluzone HD QIV 240 mcg IM injection on Day 1 (vaccination 1) followed by an IM injection containing both Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 29 (vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"338"},{"groupId":"OG001","value":"338"}]}],"classes":[{"title":"A/Victoria","categories":[{"measurements":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"190"}]}]},{"title":"A/Tasmania","categories":[{"measurements":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"165"}]}]},{"title":"B/Washington","categories":[{"measurements":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"117"}]}]},{"title":"B/Phuket","categories":[{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"84"}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Participants After 28 Days of Administration of Influenza Vaccine","description":"Number of seroprotected participants after 28 days of administration of influenza vaccine (fluzone) were reported. Seroprotection is defined for each of the 4 influenza vaccine strains as HI titer \\>=1:40 at 28 days after the administration of a quadrivalent high-dose seasonal influenza vaccine.","populationDescription":"PPII set included all randomized participants who received the first study vaccination, and for whom immunogenicity data were available for at least one of the influenza strains in the vaccine. Samples taken after participant experienced major protocol deviation expected to impact the immunogenicity outcomes were excluded from this analysis, including those who were collected out of window.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"28 days after vaccination with fluzone on Day 1 (up to Day 29)","groups":[{"id":"OG000","title":"Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV + Placebo (CoAd Group)","description":"Participants received intramuscular (IM) injection containing both adenovirus serotype 26 pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and respiratory syncytial virus prefusion F-protein (RSV preF protein) 150 micrograms (mcg) coadministered with Fluzone high-dose (HD) quadrivalent (QIV) 240 mcg IM injection on Day 1 (vaccination 1) followed by placebo IM injection on Day 29 (vaccination 2)."},{"id":"OG001","title":"Group 2: Placebo With Fluzone HD QIV + Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received placebo IM injection coadministered with Fluzone HD QIV 240 mcg IM injection on Day 1 (vaccination 1) followed by an IM injection containing both Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 29 (vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"338"},{"groupId":"OG001","value":"338"}]}],"classes":[{"title":"A/Victoria","categories":[{"measurements":[{"groupId":"OG000","value":"323"},{"groupId":"OG001","value":"313"}]}]},{"title":"A/Tasmania","categories":[{"measurements":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"285"}]}]},{"title":"B/Washington","categories":[{"measurements":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"245"}]}]},{"title":"B/Phuket","categories":[{"measurements":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"122"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"From Day 1 up to 7 months","description":"The full analysis set (FAS) included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo).","eventGroups":[{"id":"EG000","title":"Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV (CoAd Group)","description":"Participants received intramuscular (IM) injection containing both Ad26. RSV. preF; 1\\*10\\^11 viral particles (vp) and RSV preF protein; 150 micrograms (mcg) coadministered with Fluzone high-dose (HD) quadrivalent (QIV) 240 mcg IM injection on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":385,"seriousNumAffected":2,"seriousNumAtRisk":385,"otherNumAffected":18,"otherNumAtRisk":385},{"id":"EG001","title":"Group 2: Fluzone HD QIV With Placebo (Control Group)","description":"Participants received Fluzone HD QIV 240 mcg IM injection coadministered with placebo IM injection on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":386,"seriousNumAffected":2,"seriousNumAtRisk":386,"otherNumAffected":12,"otherNumAtRisk":386},{"id":"EG002","title":"Group 1: Placebo (CoAd Group)","description":"Participants received placebo IM injection on Day 29.","deathsNumAffected":1,"deathsNumAtRisk":357,"seriousNumAffected":11,"seriousNumAtRisk":357,"otherNumAffected":1,"otherNumAtRisk":357},{"id":"EG003","title":"Group 2: Ad26/Protein preF RSV Vaccine (Control Group)","description":"Participants received IM injection containing both Ad26. RSV. preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 29.","deathsNumAffected":0,"deathsNumAtRisk":363,"seriousNumAffected":11,"seriousNumAtRisk":363,"otherNumAffected":10,"otherNumAtRisk":363}],"seriousEvents":[{"term":"Angina Pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":1,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Cardiac Arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":1,"numAtRisk":357},{"groupId":"EG003","numAffected":0,"numAtRisk":363}]},{"term":"Cardiac Failure Congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":1,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":0,"numAtRisk":363}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":0,"numAtRisk":363}]},{"term":"Proctitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":1,"numAtRisk":357},{"groupId":"EG003","numAffected":0,"numAtRisk":363}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Jaundice Cholestatic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":1,"numAtRisk":357},{"groupId":"EG003","numAffected":0,"numAtRisk":363}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":1,"numAtRisk":357},{"groupId":"EG003","numAffected":2,"numAtRisk":363}]},{"term":"Covid-19 Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Meningitis Pneumococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Pneumonia Staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":4,"numAtRisk":363}]},{"term":"Septic Shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Femoral Neck Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":1,"numAtRisk":357},{"groupId":"EG003","numAffected":0,"numAtRisk":363}]},{"term":"Femur Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":1,"numAtRisk":357},{"groupId":"EG003","numAffected":0,"numAtRisk":363}]},{"term":"Lower Limb Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":1,"numAtRisk":357},{"groupId":"EG003","numAffected":0,"numAtRisk":363}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":1,"numAtRisk":357},{"groupId":"EG003","numAffected":0,"numAtRisk":363}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":0,"numAtRisk":363}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":2,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Lung Carcinoma Cell Type Unspecified Stage Iv","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Brain Injury","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]},{"term":"Acute Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":1,"numAtRisk":357},{"groupId":"EG003","numAffected":2,"numAtRisk":363}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":1,"numAtRisk":357},{"groupId":"EG003","numAffected":0,"numAtRisk":363}]},{"term":"Decubitus Ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":385},{"groupId":"EG001","numAffected":0,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":1,"numAtRisk":363}]}],"otherEvents":[{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":385},{"groupId":"EG001","numAffected":4,"numAtRisk":386},{"groupId":"EG002","numAffected":1,"numAtRisk":357},{"groupId":"EG003","numAffected":8,"numAtRisk":363}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":385},{"groupId":"EG001","numAffected":8,"numAtRisk":386},{"groupId":"EG002","numAffected":0,"numAtRisk":357},{"groupId":"EG003","numAffected":2,"numAtRisk":363}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application."},"pointOfContact":{"title":"Director Biomarkers Viral Vaccines","organization":"Janssen Vaccines & Prevention B.V.","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-02-07","uploadDate":"2023-08-14T06:25","filename":"Prot_000.pdf","size":1725722},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-07-05","uploadDate":"2023-08-14T06:25","filename":"SAP_001.pdf","size":1123481}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D007252","term":"Influenza Vaccines"}],"ancestors":[{"id":"D014765","term":"Viral Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}